Carmat S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CKMTF research report →
Companywww.carmatsa.com
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It The company was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
- CEO
- Stephane Piat
- IPO
- 2018
- Employees
- 182
- HQ
- Vélizy-Villacoublay, FR
Price Chart
Valuation
- Market Cap
- $85.19M
- P/E
- -0.04
- P/S
- 0.91
- P/B
- -0.04
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- -702.86%
- Net Margin
- -734.29%
- ROE
- 106.81%
- ROIC
- -191.84%
Growth & Income
- Revenue
- $2.80M · 652.69%
- Net Income
- $-53,900,000 · -0.41%
- EPS
- $-2.18 · 8.02%
- Op Income
- $-52,500,000
- FCF YoY
- -4.24%
Performance & Tape
- 52W High
- $12.75
- 52W Low
- $12.75
- 50D MA
- $12.75
- 200D MA
- $12.75
- Beta
- 1.38
- Avg Volume
- 0
Get TickerSpark's AI analysis on CKMTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CKMTF Coverage
We haven't published any research on CKMTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CKMTF Report →